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The Role of Amrinone in Potential Heart Transplant Patients 
With Pulmonary Hypertension 
G. Michael Deeb, MD and Steven F. Bolling, MD 
Orthotopic heart transplantation is contraindicated 
in patients with pulmonary hypertension and an 
elevated pulmonary vascular resistance. In an at- 
tempt to make otherwise unacceptable patients 
possible candidates for heart transplantation, amri- 
none was administered intravenously to 27 individu- 
als with a transpulmonary gradient and pulmonary 
vascular resistance in the abnormal range. Twenty- 
four of 27 patients (89%) responded positively. 
Twenty-one of 27 (78%) went on to transplantation 
and 20 of 21 (95%) survived the procedure. A second 
study compared amrinone therapy with conventional 
therapy in 38 potential transplant candidates with 
pulmonary hypertension. Amrinone was more effec- 
tive in reducing pulmonary hypertension than conven- 
P ULMONARY hypertension (PHT) has been a significant clinical problem since the 
inception of orthotopic heart transplantation. It 
quickly became apparent that heart transplant 
recipients with underlying PHT (pulmonary arte- 
rial systolic pressures greater than 50 mm Hg) 
had severe difficulty being weaned from cardio- 
pulmonary bypass at the time of their transplan- 
tations, secondary to right-sided heart failure. 
Isoproterenol, a P-agonist, is generally adminis- 
tered during the weaning process to stimulate the 
newly transplanted heart and to initiate vigorous 
ventricular contraction. In the presence of PHT, 
the right ventricle will begin to distend as wean- 
ing from cardiopulmonary bypass proceeds, and 
contractility will markedly diminish. The right 
ventricle will eventually overdistend and cease 
contracting. Ultimately, the patient will become 
hypotensive and have minimal organ perfusion. 
Various techniques have been used to avoid this 
poor outcome, including the administration of 
isoproterenol as an infusion into the right atrium 
and a simultaneous epinephrine infusion into the 
left atrium. This modality of therapy would 
potentially increase the systemic blood pressure 
but would do little or nothing for the overall 
cardiac output and systemic perfusion. Alterna- 
tive procedures for patients with significant PHT 
who are not orthotopic heart transplantation 
candidates include heart-lung transplantation or 
the heterotopic heart transplant procedure. Stud- 
ies of pulmonary hemodynamics separated pa- 
tients into certain distinct categories. Heart-lung 
tional therapy with high-dose diuretics, digitalis, and 
captopril (88% v 83%). Survival rate of those await- 
ing transplantation was also significantly higher in 
the amrinone group (91% v 83%). Although the 
protocol for comparing the two regimens does not 
allow for extrapolation of the results (amrinone was 
administered in-hospital under close monitoring, 
whereas conventional therapy was self-adminis- 
tered at home), the findings confirm the clinical 
impression that amrinone seems more effective and 
safer than conventional therapy in the treatment of 
potential heart transplant patients with pulmonary 
hypertension. 
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transplantation was reserved for those patients 
with primary PHT or fixed PHT, secondary to 
left-to-right shunt and the diagnosis of Eisen- 
menger’s syndrome. 
PULMONARY DYNAMICS 
Not all patients with high pulmonary pres- 
sures suffered disastrous fates with orthotopic 
heart transplant; some were successfully weaned 
off bypass quite easily and recovered remarkably 
well. In an effort to identify the patients who 
would have difficulty, attention was focused on 
pulmonary hemodynamics. 
Patients with elevated pulmonary pressures 
secondary to heart failure without a left-to-right 
shunt were the remaining group that needed to 
be subdivided further. These prospective heart 
transplant candidates fell into two groups, those 
patients with responsive pulmonary vasculature 
who could accept an orthotopic transplant and 
those with nonresponsive hemodynamics, who 
would best be accommodated by a heterotopic 
procedure. Kormos et al’ noted that the two most 
significant indicators of outcome in orthotopic 
heart transplantation were the transpulmonary 
gradient (TPG) and the pulmonary vascular 
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resistance (PVR). It was noted that when a 
patient’s TPG (pulmonary arterial mean pres- 
sure minus pulmonary capillary wedge pressure) 
was greater than 15 mm Hg and the PVR was 
greater than 5 Wood’s units (WU), the operative 
mortality with orthotopic heart transplantation 
was approximately 25%, secondary to acute right- 
sided heart failure.’ Kirklin et al2 verified these 
findings using analysis of variance for risk factors 
in 61 orthotopic heart transplant patients and 
showed that elevated PVR caused a significant 
increase in the perioperative mortality. There- 
fore, efforts were directed to identifying patients 
with elevated TPG and/or PVR and targeting 
therapy to reduce the TPG to less than 15 mm 
Hg and the PVR to less than 5 WU. 
It was decided that the majority of patients 
with elevated pulmonary hemodynamics second- 
ary to primary congestive heart failure had 
increases in their pulmonary pressures, second- 
ary to a high left ventricular end-diastolic pres- 
sure. Therefore, decreasing the systemic after- 
load should have ultimately reduced the 
pulmonary pressures and vascular resistances in 
these patients. Accordingly, at the time of right- 
sided heart catheterization, a patient with a 
pulmonary arterial systolic pressure greater than 
50 mm Hg and a TPG greater than 15 mm Hg or 
a PVR greater than 5 WU should undergo 
immediate systemic afterload reduction with in- 
travenous sodium nitroprusside. If the patient 
responds to this maneuver with a decrease in the 
TPG to less than 15 mm Hg and/or the PVR to 
less than 5 WU, then the patient should be 
considered a responder and placed on oral after- 
load reduction therapy. However, a large number 
of patients do not immediately respond with 
decreases in their TPG and PVR into an accept- 
able range and therefore are not considered 
candidates for orthotopic heart transplantation. 
It is conceivable that patients do not immediately 
respond because they have had chronic elevation 
of pressures caused by heart failure; they may 
require prolonged therapy. 
AMRINONE THERAPY 
Amrinone (Inocor, Winthrop, New York, 
NY) increases inotropy secondary to phosphodi- 
esterase inhibition and causes smooth muscle 
relaxation and vasodilation. It seems to be an 
excellent drug for reducing the PVR in those 
patients who do not respond to sodium nitroprus- 
side. Eichorn et al3 reported that amrinone re- 
duces right ventricular afterload and causes an 
increase in cardiac index and right ventricular 
systolic performance with a significant decrease 
in pulmonary end-systolic pressure. Therefore, 
they studied 27 patients who, on right-sided 
heart catheterization, had TPG greater than 15 
mm Hg and PVR greater than 5 WU and were 
unresponsive to a challenge with sodium nitro- 
prusside. These patients were thought to have 
pulmonary hypertension secondary to congestive 
heart failure, that was unresponsive to immedi- 
ate left ventricular unloading; therefore, they 
were thought to be good candidates for a trial 
with prolonged intravenous amrinone therapy.4 
The patients were admitted to the intensive 
care unit, where they underwent loading with 
0.75 mg/kg of intravenous amrinone over a 15 
minute period, and subsequently received a con- 
tinuous infusion beginning at 2.5 pg/kg/min, 
titrating the dose up to a maximum of 20 
pg/kg/min with a goal of achieving a pulmonary 
arterial systolic pressure less than 50 mm Hg, a 
TPG less than 15 mm Hg, and a PVR of less than 
5 WU. Pulmonary and systemic hemodynamics 
were continously monitored, as were serum elec- 
trolytes and renal and hepatic functions. Serum 
platelet levels were also followed. After 48 hours, 
the systemic and pulmonary arterial catheters 
were removed, and the patients were recatheter- 
ized on a weekly basis. Twenty-four of 27 previ- 
ously unresponsive pulmonary hypertensive pa- 
tients (89%) responded to this modality of therapy 
with a decrease in their pulmonary indices into a 
range acceptable for orthotopic heart transplan- 
tation. The average dose of amrinone was 9 
pg/kg/min. Patients required a mean of 3 days 
from the initiation of therapy until the target 
goals were attained. Patients who did not respond 
within the first week never responded subse- 
quently. Twenty-one of the 24 patients who 
responded were fortunate enough to receive do- 
nor hearts and underwent orthotopic heart trans- 
plantation. Twenty of the 21 patients (95%) who 
received transplants survived the procedure and 
were discharged. 
The one patient who did not survive the 
procedure died of acute right-sided heart failure. 
This patient had difficulty being separated from 
cardiopulmonary bypass, necessitating mechani- 
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cal assistance. The patient was an &year-old girl 
who had congestive cardiomyopathy associated 
with pulmonary hypertension. She entered the 
amrinone trial and responded to therapy with a 
decrease in her pulmonary parameters. Intrave- 
nous amrinone was discontinued, and she was 
discharged; it was planned to recatheterize her 
biweekly. Ten days after her discharge a donor 
organ became available, and at the time of her 
readmission her pulmonary pressures and resis- 
tance were, once again, unacceptable. She was 
again given amrinone, but did not respond imme- 
diately, and underwent orthotopic heart trans- 
plantation, but did not survive. Therefore, ther- 
apy has been continued on all subsequent patients 
until transplantation. 
It was concluded that intravenous amri- 
none was an adequate drug for reducing pulmo- 
nary pressures and vascular resistance into an 
acceptable range for orthotopic heart transplant 
in these previously unresponsive patients, as 
noted by the 89% response rate. It was also felt 
that this was an effective modality of therapy 
since the perioperative mortality was reduced 
from 25% to 5%. 
sive to left ventricular unloading with sodium 
nitroprusside received conventional therapy. Ta- 
ble 1 shows the drug regimens of the patients 
with pulmonary hypertension who received con- 
ventional therapy. All 16 patients were on furo- 
semide, (average of 360 mg/d), with 9 patients 
also on metolazone (10 mg/d) and an additional 
5 patients on bumetanide (5 mg/d). Ten of 16 
patients (63%) were responsive to this therapy. 
There was an average of 8 days from the onset of 
therapy until the patients reached their desired 
hemodynamic parameters. Suitable donor or- 
gans were obtained for 7 of the 10 responding 
patients, and they underwent successful trans- 
plantation. Of the 16 patients treated with conven- 
tional therapy, 6 died suddenly at home (63% 
survival awaiting transplant). 
Amrinone Versus Conventional Therapy 
Therapy While Awaiting Transplantation 
However, prolonged intravenous amrinone 
is not practical because of the long wait for donor 
organs, Currently at this institution the average 
wait for a donor heart is 8 to 12 months. Since 
continuous in-hospital intravenous therapy is 
unreasonable for such a length of time, a more 
conventional medical regimen was initiated, in- 
cluding oral digoxin at 0.25 mg/d, an oral 
angiotensin-converting enzyme inhibitor (capto- 
pril), and high-dose oral diuretics. Sixteen pa- 
tients, who underwent standard right heart cath- 
eterization for pretransplant workup, met the 
protocol criteria for unacceptable pulmonary 
hemodynamics, and were not immediately respon- 
Comparison of patients treated with conven- 
tional therapy with an age-matched group from 
the amrinone patient pool was undertaken.5 
Twenty-two of the 27 previously discussed pa- 
tients were included in the age-matched amri- 
none group. There was no significant difference 
in the rate of response between the two groups. 
Nineteen of 22 patients (86%) in the amrinone 
group responded, and 10 of 16 patients (63%) in 
the conventional therapy group responded 
(P = 0.053). Comparing the survival rate in the 
two groups, 20 of 22 patients in the amrinone 
group survived (91’%), whereas only 10 of 16 
patients in the conventional group survived (63%). 
This difference was significant at the P -c 0.05 
level. However, it may not be fair to compare 
these two groups because the amrinone group 
received intravenous therapy in the hospital while 
being monitored, whereas the conventional group 
was at home. The causes of death while awaiting 
transplant were different between the two groups. 
Two patients in the amrinone group died of 
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Conventional Therapy 
No. of No. of 
Patients Name DOSE Patients 
9 Furosemide 360 mg/d 16 
- Digoxin 0.250 mg/d 16 
- Captopril 37.5 mg/d 11 
2 Metolazone 20 mg/d 9 
- Bumetanide 6 mgld 5 
22 Amrinone - - 
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progressive left ventricular failure unresponsive 
to amrinone therapy, whereas the outpatients 
receiving conventional therapy died suddenly, 
quite possibly from dysrhythmias induced by the 
high dose of diuretics and digoxin. 
Analysis of amrinone and conventionally 
treated patients showed no significant differences 
in the pretreatment pulmonary and systemic 
hemodynamic parameters. Comparison of the 
pretreatment versus posttreatment mean pulmo- 
nary and systemic parameters in the group receiv- 
ing amrinone therapy showed there were signifi- 
cant reductions in pulmonary pressures, TPG, 
and PVR. There was also a significant increase in 
the cardiac output with no significant change in 
the heart rate or the systemic arterial or venous 
pressures. The systemic vascular resistance fell, 
but not significantly (Table 2). Comparison of 
pretreatment versus posttreatment mean hemody- 
namic values for patients receiving conventional 
therapy showed both the pulmonary and the 
systemic hemodynamics significantly changed 
(Table 3). 
Therefore, it was concluded that the de- 
sired pulmonary changes with the conventional 
group were secondary to systemic hemodynamic 
changes, but that the changes in the amrinone- 
treated group were quite possibly caused by a 
primary vasodilation of the pulmonary vascula- 
ture. To further support this concept, comparison 
of post-therapy parameters between the two 
different treatment groups showed a significant 
Table 2. Amrinone Therapy: Prehemodynamics Versus 
Posthemodynamics (N = 22) 
Prehemodynamics P Value Posthemodynamics 
BUN (mg/dL) 28.8 + 2.3 NS 30.2 f 1.6 
Creatinine 
(mg/dL) 1.3 f 0.06 NS 1.39 f 0.07 
PAM (mm Hg) 44.3 + 1.6 tO.OOO1 29.0 f 1.5 
PCWP (mm Hg) 25.2 + 1.1 <0.0001 18.5 + 1.2 
TPG (mm Hg) 19.0 + 1.2 <0.0001 10.9 f 0.9 
CO (L/min) 3.5 * 0.3 to.0015 4.56 + 0.3 
PVR (WU) 5.67 ? 0.4 <0.0001 2.49 & 0.2 
MAP (mm Hg) 79.0 f 3.4 NS 80.3 f 3.0 
CVP (mm Hg) 12.5 f 1.9 NS 8.3 + 1.8 
SVR (WU) 20.8 f 2.1 NS 16.4 f 1.2 
Abbreviations: BUN, blood urea nitrogen: PAM, pulmo- 
nary arterial mean pressure: PCWP, pulmonary capillary wedge 
pressure; TPG, transpulmonary gradient: PVR, pulmonary vascu- 
lar resistance: MAP, mean arterial pressure: CVP, central venous 
pressure; SVR, systemic vascular resistance. 
Table 3. Conventional Therapy Prehemodynamics Versus 
Posthemodynamics (N = 16) 
Prehemodynamics P Value Posthemodynamics 
BUN (mg/dL) 27.7 f 3.5 NS 30.2 f 2.5 
Creatinine (mg/dL) 1.4 f 0.1 NS 1.39 * 0.09 
PAM (mm Hg) 46.2 + 1.8 0.0001 32.2 + 2.2 
PCWP (mm Hg) 27.7 + 1.8 0.002 18.9 zt 1.8 
TPG (mm Hg) 18.2 + 1.0 0.003 13.4 f 1.0 
CO (L/mini 3.6 f 0.2 0.03 4.2 f 0.15 
PVR (WU) 5.1 f 0.4 0.003 3.3 f 0.3 
MAP (mm Hg) 85.0 f 3.6 0.03 75.7 f 2.0 
CVP (mm Hg) 11.7 * 1.9 0.017 5.7 f 1.3 
SVR (WU) 21.2 + 1.3 0.02 16.6 f 1.1 
Weight (kg) 84.6 f 3.6 NS 78.9 + 3.4 
Abbreviations: See Table 2. 
difference only in the PVR. Although both groups 
showed significant reductions in PVR during the 
presetting versus postsetting, the decrease in the 
PVR in the amrinone group was significantly 
greater than that in the conventional group. This 
finding is in light of the fact that there was no 
significant difference in the PVR between the 
two groups prior to therapy. 
CONCLUSION 
Intravenous amrinone is an excellent ther- 
apy for patients with pulmonary hypertension, 
secondary to congestive heart failure (90% re- 
sponse rate). Patients who respond to amrinone 
therapy can subsequently undergo orthotopic 
heart transplantation with a ~5% operative risk. 
The time of onset from initiation of therapy until 
desired parameters were attained was 3 days, but 
this duration could be significantly shortened by 
increasing the loading dose and starting at a 
higher continuous intravenous infusion rate. Us- 
ing more current loading protocols recommended 
by Hines and Levy would allow a much more 
rapid therapeutic blood level of amrinone to be 
achieved and could quite possibly shorten the 
duration of treatment [see Levy and Bailey, p 10, 
and Hines, p 24, in this issue]. If higher doses of 
intravenous amrinone are given, the required 
duration of therapy decreases to 2 to 3 hours, and 
it may be possible to test patients for their 
responsiveness to amrinone on an acute basis in 
the catheterization laboratory. These patients 
could be discharged and treated again with 
amrinone at the time of readmission for transplan- 
tation. Currently, prolonged amrinone therapy is 
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limited because it requires continual therapy, 
and the present wait for donor hearts ranges from 
8 months to 1 year. Conversely, conventional 
therapy is more practical and has a reasonable 
success rate (63%). Once the patients’ parame- 
ters are acceptable for orthotopic heart transplan- 
tation, the perioperative success rate is excellent. 
However, the preoperative mortality rate is high 
with conventional therapy, believed to be second- 
ary to sudden death from dysrhythmias. There- 
fore, all the patients receiving conventional ther- 
apy are also being treated with amiodarone until 
the time of transplantation. 
The ideal therapy may be an oral phospho- 
diesterase inhibitor that could be used in an 
outpatient setting, yet would show the excellent 
response rate seen with the intravenous form of 
amrinone. 
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